IPP Bureau

Known Medicine partners with Duke University to predict lung cancer response to drug treatments
Known Medicine partners with Duke University to predict lung cancer response to drug treatments

By IPP Bureau - March 04, 2022

Collaboration aims to capture patient-to-patient variability to determine the best treatment for every cancer

Scientific leaders signal major breakthroughs in elimination of cervical and anal cancers
Scientific leaders signal major breakthroughs in elimination of cervical and anal cancers

By IPP Bureau - March 04, 2022

To mark International HPV Awareness Day on March 4th 2022, the International Papillomavirus Society (IPVS) has warmly welcomed two major advances in the elimination of cervical and anal cancers

MFine launches heart rate monitoring tool on its App
MFine launches heart rate monitoring tool on its App

By IPP Bureau - March 04, 2022

It plans launch various other health monitoring tools for smartphones, making existing devices obsolete

Aster Labs expands across south and west India
Aster Labs expands across south and west India

By IPP Bureau - March 04, 2022

A total of 17 labs will be operational across the country by this month

USFDA refuses to grant EUA to Covaxin for padeatric use
USFDA refuses to grant EUA to Covaxin for padeatric use

By IPP Bureau - March 04, 2022

Covaxin is not approved in the USA for any age group

MIBCON NDC offers CO2 Optimisation module
MIBCON NDC offers CO2 Optimisation module

By IPP Bureau - March 04, 2022

The CO2 Optimization module is one of the four modules (Product Costing, BoM Management, CO2 Optimization, Supplier Strategy) within the entire NDC Simulation Suite

Govt announces over Rs 100 crore investment for Ayush sector in Nagaland
Govt announces over Rs 100 crore investment for Ayush sector in Nagaland

By IPP Bureau - March 04, 2022

Ten new Ayush hospitals and one Ayurvedic college will be set up in Nagaland and Mizoram

Alkem licenses technology from Harvard to treat ischemic injury and vascular diseases
Alkem licenses technology from Harvard to treat ischemic injury and vascular diseases

By IPP Bureau - March 03, 2022

Novel delivery of established growth and neurotrophic factors enables local, sustained release for greater efficacy

Cipla gets approval from SEC to conduct Paxlovid trials
Cipla gets approval from SEC to conduct Paxlovid trials

By IPP Bureau - March 03, 2022

Paxlovid consists of nirmatrelvir, which inhibits a SARS-CoV-2 protein to stop the virus from replicating, and ritonavir, which slows down nirmatrelvir’s breakdown to help it remain in the body for a longer period at higher concentrations

Brinton ties up with Scholl Wellness Company
Brinton ties up with Scholl Wellness Company

By IPP Bureau - March 03, 2022

Brinton Pharmaceuticals enters exclusive sales and distribution rights of Scholl foot care products including Krack cream

IIFL AMC funds acquire stake in OmniActive Health Technologies
IIFL AMC funds acquire stake in OmniActive Health Technologies

By IPP Bureau - March 03, 2022

OmniActive seeks to improve lives by enhancing nutrition and wellness through science and innovation

Limited impact of short-term disruptions, growth momentum to continue in FY 23
Limited impact of short-term disruptions, growth momentum to continue in FY 23

By IPP Bureau - March 03, 2022

Large players are adequately capitalised to make bigger investments to adjust for the ongoing fundamental shift in market opportunities

IHub-Data and IIIT-Hyderabad offer course on drug discovery
IHub-Data and IIIT-Hyderabad offer course on drug discovery

By IPP Bureau - March 03, 2022

12-week certificate course commences on March 10th 2022

WHO includes molnupiravir in its Covid-19 treatment guidelines
WHO includes molnupiravir in its Covid-19 treatment guidelines

By IPP Bureau - March 03, 2022

This ninth update of WHO’s guideline on therapeutics includes a recommendation that casirivimab-imdevimab not be used for patients infected with the Omicron variant

Avenge Bio announces peer-reviewed publication on preclinical proof of concept for LOCOcyte platform technology
Avenge Bio announces peer-reviewed publication on preclinical proof of concept for LOCOcyte platform technology

By IPP Bureau - March 03, 2022

Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal

Latest Stories

Interviews

Packaging